NexGel, Inc. (NXGL) - 10-K Filing Summary
Business Context and Reporting Period
Company: NexGel, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: NexGel manufactures high water content, electron beam cross-linked hydrogels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company operates four distinct lines of business: Contract Manufacturing, Custom & White Label, Consumer Branded Products (including MedaGel, Kenkoderm, and Silly George), and Medical Devices (NEXDrape, NEXDerm). The company is classified as a "smaller reporting company" and an "emerging growth company."
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net Revenues | $8,688 | $4,089 |
| Gross Profit | $2,748 | $374 |
| Gross Margin | 31.6% | 9.1% |
| Net Loss (Attributable to NexGel) | $(3,281) | $(3,157) |
| Operating Loss | $(3,554) | $(3,477) |
| Cash and Cash Equivalents (End of Period) | $1,807 | $2,700 |
| Working Capital | $2,644 | $2,503 |
| Net Cash Used in Operating Activities | $(3,867) | $(3,236) |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 112.5% to $8.688 million, driven primarily by the acquisition of the "Silly George" brand (contributing $2.889 million in gross revenue post-acquisition) and growth in branded consumer products.
- Margin Expansion: Gross margin improved significantly from 9.1% in 2023 to 31.6% in 2024, attributed to the higher-margin mix of branded consumer products.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 66.1% to $6.224 million. Key drivers included a 404.5% increase in advertising and Amazon fees ($2.220 million) due to marketing Kenkoderm and Silly George, and a 37.8% increase in compensation and benefits.
- Acquisitions: The company acquired the Silly George brand in May 2024 (cash and stock consideration of $600,000) and the Kenkoderm brand in December 2023.
Guidance, Outlook, Risks, and Contingencies
- Going Concern Warning: The filing explicitly states that recurring losses and negative cash flows raise "substantial doubt" about the company's ability to continue as a going concern. Management expects to be cash flow positive by the end of fiscal year 2025 but notes that additional capital may be required.
- Capital Raising: The company completed a rights offering in November 2024, raising approximately $2.0 million in gross proceeds to fund working capital. Additional equity or debt raises may be necessary.
- Internal Control Weaknesses: Management identified material weaknesses in internal controls over financial reporting, specifically regarding the review/approval of accounting journal entries and "super user" access rights in financial systems.
- Strategic Outlook: The company plans to continue its "roll-up" strategy for consumer products, develop proprietary medical devices (NEXDrape, NEXDerm), and pursue licensing partnerships for medical devices rather than direct commercialization.
- Risks: Key risks include reliance on Amazon/Shopify for sales, lack of long-term customer contracts (sales are purchase-order based), supply chain concentration (reliance on Dow and BASF for polymers), and intense competition from larger entities like Johnson & Johnson and 3M.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.8 million cash balance against the $3.9 million annual operating cash burn to assess the timeline for potential dilution or insolvency.
- Acquisition Integration: Review the performance of the Silly George and Kenkoderm brands to determine if the revenue growth is sustainable without further heavy marketing spend.
- Internal Controls: Monitor the remediation plan for the identified material weaknesses in financial reporting to ensure future financial statement reliability.
- Customer Concentration: Confirm the status of the major customer that represented 20% of revenue in 2023, as the company currently has no long-term contract with them.
- Dilution Risk: Assess the impact of outstanding warrants (4.76 million shares) and options (588,397 shares) on future share count and earnings per share.